sar422459
Gene therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01367444)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Retinal-specific phospholipid-transporting ATPase ABCA4Supplementation
supplementation - Abca4
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sar422459
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01736592 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2012 | CHNO des Quinze-Vingts, Oregon Health and Science University, Sanofi |
| NCT01367444 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2011 | CHNO des Quinze-Vingts, Oregon Health and Science University, Sanofi |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CHNO des Quinze-Vingts | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Oregon Health and Science University | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Sanofi | For profit | 2 | 2 | 1 | 2011 |
3 organizations
Page 1 / 1